GORT

Reviews

Full-Life Technologies Closes $47.3M Series B Financing

Di: Everly

Full-Life Technologies|Home has raised a total funding of $94.3M over 4 rounds. Its first funding round was on Dec 21, 2021. Its latest funding round was a Series B round on

Medasense Biometrics Closes $8M Series B Financing - FinSMEs

Shanghai, China & Brussels, Belgium – May 26, 2022 – Full-Life Technologies (“Full-Life”) today announced it completed a $37 million (USD) Series A financing round to

Full-Life Technologies|Home funding & investors

Full-Life completed $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities.

Full-Life Technologies raised $16000000 on 2024-01-03 in Debt Financing. New. Resources. Advanced Search. Start Free Trial . Talk With Sales. Pricing. Log In. Log In.

  • Lunaphore closes a CHF 5.3M Series B financing round
  • Recuro Health Closes $47 Million Series B Financing Led
  • Full-Life Technologies|Home funding & investors
  • Full-Life Technologies’ Post

X-ray Crystal Structure Analysis of Protein Cryo-EM Technology Platform . Hit Discovery

Full-Life Technologies Closes $47.3M Series B Financing. The firm will use the funds to grow its radiopharmaceutical manufacturing capabilities and advance its pipeline of cancer therapies.

SHANGHAI and GEMBLOUX, Belgium and HEIDELBERG, Germany, Jan. 3, 2024 /PRNewswire/ — Full-Life Technologies („Full-Life“), a fully integrated global BREAKING NEWS

Recent biotech series B funding rounds. January 2024: Vico Therapeutics (Netherlands): $60 million (€54 million) series B | RNA modulation | phase 1/2 in spinocerebellar ataxia type 3; Full

Recuro Health Closes $47 Million Series B Financing Led

SHANGHAI and GEMBLOUX, Belgium and HEIDELBERG, Germany, Jan. 3, 2024 /PRNewswire/ — Full-Life Technologies („Full-Life“), a fully integrated global radiotherapeutics

SHANGHAI and GEMBLOUX, Belgium and HEIDELBERG, Germany, Jan. 3, 2024 /PRNewswire/ — Full-Life Technologies (“Full-Life”), a fully integrated global radiotherapeutics

Lunaphore Technologies SA, a Swiss medtech firm developing innovative next-generation devices for cancer tissue diagnostics*, announces closing of CHF 5.3M in Series B

NEW YORK – Full-Life Technologies on Thursday said it raised $47.3 million in Series B equity financing, which it will use to advance a pipeline of radiopharmaceuticals for

SHANGHAI and GEMBLOUX, Belgium and HEIDELBERG, Germany, Jan. 3, 2024 /PRNewswire/ — Full-Life Technologies („Full-Life“), a fully integrated global radiotherapeutics

  • Recent biotech fundings: The 2024 tracker
  • Full-Life Technologies Raises $37M in Series A Financing
  • Full-Life Technologies Secures USD $47.3 Mn Series B Funding
  • Recuro Health Closes $47 Million Series B Financing Led by
  • AboutFull-Life Technologies-About Us-From Half-Life to Full-Life

Full-Life Technologies will showcase preclinical data of its NTSR1-targeted RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting. Shanghai, China,

Shanghai, Gembloux, Belgium, and Heidelberg, Germany – Jan. 4, 2024 – Full-Life Technologies („Full-Life“), invested by Viva BioInnovator (VBI), is a fully integrated global radiotherapeutics

Home / Proteins and Peptides / Global radiotherapeutics company Full-Life Technologies announces USD $47.3 million Series B financing, Prosperity7 Ventures jointly

With completion of such financing, Full-Life has secured more than $110 million funding since its inception in August 2021, including equity financing, loan facilities, and

Full-Life Technologies, a fully integrated global radiotherapeutics company announced the completion of $63.3 million financing, comprised of $47.3 million in Series B

Lunaphore Closes CHF5.3M Series B Financing Round - FinSMEs

DALLAS–(BUSINESS WIRE)–Recuro Health, an integrated digital health solutions company designed to transition the U.S. healthcare system from a reactive, disease-focused

Recently, Full-Life Technologies („Full-Life“), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing,

any’s radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDCTM. With completion of such financing, Full-Life has

Recuro Health Closes $47 Million Series B Financing Led by ARCH Venture Partners, Advancing Innovative Virtual-First Care Service . Business Wire. April 11, 2023 7:25

Full-Life completed $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. 2024. 1 2023. 12

Global radiotherapeutics company Full-Life Technologies announces USD $47.3 million Series B financing, Prosperity7 Ventures jointly leads the round

series B, venture capital funding Full-Life Technologies Raises USD $47.3M in Series B Funding

Full-Life Technologies („Full-Life“), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B

With completion of such financing, Full-Life has secured more than $110M funding since its inception in August 2021, including equity financing, loan facilities, and government

Full-Life Technologies („Full-Life“), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in

With completion of such financing, Full-Life has secured more than $110 million funding since its inception in August 2021, including equity financing, loan facilities, and

Recuro Health (Recuro), an integrated digital health solutions company designed to transition the U.S. healthcare system from a reactive, disease-focused model to a proactive

Full-Life completed $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. 2024. 1 2023. 12